Top Injectable Manufacturer in Chad – Reliable Pharmaceutical Solutions
- Maulik Sudani
- Jul 28
- 9 min read
Last Updated: July 28, 2026
TL;DR: Chad imports more than 90% of the medicines it consumes and has no meaningful domestic sterile injectable manufacturing capacity. Registration is administered by the Direction Generale de la Pharmacie, du Medicament et des Laboratoires (DGPML) under the Ministry of Public Health, applying Loi n024/PR/2000 relative a la Pharmacie. As a CEMAC member state alongside Cameroon, Central African Republic, Congo, Gabon and Equatorial Guinea, Chad has adopted the CTD dossier format harmonised regionally by OCEAC since 2013, but a national Autorisation de Mise sur le Marche (AMM) is still required for each product, since full CEMAC-wide mutual recognition remains a work in progress targeted for 2027. Chad has not ratified the Hague Apostille Convention, so certificates of pharmaceutical product, GMP certificates and powers of attorney require full consular legalisation rather than a single apostille stamp. Demand is driven by a heavy malaria and meningitis-belt disease burden and by one of the largest displacement crises in Africa, with more than 2.25 million forcibly displaced people sheltering in the country, including over 844,000 Sudanese refugees who have crossed the border since April 2023. Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, and pharmaceuticals are already India's largest single export category to Chad, worth US$38.73 million in 2024.
Key Takeaways
Know the regulator and the regional layer above it. Chad's Direction Generale de la Pharmacie, du Medicament et des Laboratoires (DGPML), under the Ministry of Public Health, administers registration under Loi n024/PR/2000 relative a la Pharmacie. As a CEMAC member alongside Cameroon, Central African Republic, Congo, Gabon and Equatorial Guinea, Chad has adopted the CTD dossier format harmonised by OCEAC since 2013 - but a national AMM is still required product by product, because full mutual recognition across the CEMAC zone is targeted for 2027 and is not yet in force.
A licensed local partner is mandatory, and expect French. Only a licensed pharmacist or medical officer may operate a pharmaceutical establishment in Chad, and importation requires prior authorisation from DGPML that functions as a technical clearance ahead of customs release. French is the working language of Chad's administration and of the CEMAC/OCEAC framework, so plan for a French-language dossier and correspondence rather than an English-only submission.
Legalisation, not apostille. Chad has not ratified the Hague Apostille Convention. Certificates of pharmaceutical product, GMP certificates, free-sale certificates and powers of attorney all need the full consular legalisation chain - notarisation, home-country authentication, then legalisation at the Chadian embassy - before DGPML and Chadian customs will accept them.
Demand is driven by disease burden and mass displacement. Malaria is the leading cause of consultations (42%), hospitalisations (32%) and hospital deaths (30%) in Chad, which introduced the malaria vaccine in 2024; the country also sits inside the African meningitis belt and recorded measles and meningitis C outbreaks in 2024. On top of that, Chad now hosts more than 2.25 million forcibly displaced people, including over 844,000 Sudanese refugees who arrived since April 2023, driving humanitarian demand for injectable anti-infectives, antimalarials and IV fluids far beyond what the country's near-zero sterile manufacturing base can supply on its own.
Introduction: Why an Injectable Manufacturer in Chad Must Meet Global Standards
More than 90% of the medicines consumed in Chad are imported, and the country has essentially no domestic sterile injectable manufacturing base - what local production exists is limited to small-scale repackaging and simple oral and topical formulations, not aseptically filled ampoules or vials. Against that gap, pharmaceuticals are already India's single largest export category to Chad, having grown from about US$20 million in 2022 to US$38.73 million in 2024, and Chad's participation in India's TEAM-9 initiative for West and Central African cooperation gives that trade relationship an active diplomatic channel as well as a commercial one. For any manufacturer able to combine WHO-GMP quality with the patience the Chadian registration process demands, that is a wide and largely uncontested opening.
Global standards matter in Chad because the demand behind that import gap is unusually acute. The country is one of the most malaria-affected in the Sahel, sits inside the African meningitis belt, recorded measles and meningitis C outbreaks in 2024, and is simultaneously absorbing one of the world's fastest-growing refugee populations as the Sudan conflict spills across its eastern border - more than 2.25 million people forcibly displaced in total, including over 844,000 Sudanese refugees since April 2023. That combination of endemic disease burden and humanitarian emergency means injectable anti-infectives, antimalarials and IV fluids are needed continuously and at volume, not occasionally. The differentiator for a serious exporter is the same one that applies everywhere: WHO-GMP certification, ISO Class 5 aseptic filling, complete per-batch certificates of analysis, and a marketing authorisation secured before the shipment departs India, not negotiated after it lands in N'Djamena.
What Sets a World-Class Injectable Manufacturer in Chad Apart
The first differentiator is sterile manufacturing capability that would satisfy an inspector anywhere, because Chad itself has almost no domestic reference point for one. Farbe Firma runs its Gujarat facility to WHO-GMP standards with ISO Class 5 aseptic filling under unidirectional airflow, validated sterilisation and filtration, routine media fills and a documented contamination-control strategy. With no meaningful local sterile injectable industry to benchmark against or fall back on, Chadian buyers are, in effect, importing the entire quality system along with the product - which makes the manufacturer's own documentation the whole basis of trust.
The second differentiator is understanding that Chad's regional CTD adoption does not remove the national registration step. As a CEMAC member, Chad applies the CTD dossier format harmonised by OCEAC since 2013, which is a genuine advantage for an exporter already filing in CTD elsewhere - but a national Autorisation de Mise sur le Marche from DGPML is still required for each product, because full mutual recognition across the CEMAC bloc is not yet operational (the EU/France-backed REG-PHARMA project is targeting a fully harmonised framework by 2027, not before). Equally important is getting the paperwork chain right: Chad has not ratified the Hague Apostille Convention, so every certificate of pharmaceutical product, GMP certificate and power of attorney needs full consular legalisation through the Chadian embassy, and the dossier itself should be prepared and submitted in French given the working language of both DGPML and the CEMAC/OCEAC framework.
Quality Systems Behind Every Batch We Ship to Chad
Every Farbe Firma injectable batch destined for Chad is released only once the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by validated HPLC or GC methods against USP, BP, IP or EP monographs; water content by Karl Fischer for lyophilised presentations; sterility by membrane filtration or direct inoculation; bacterial endotoxins by LAL; and particulate matter, pH, osmolality and fill-volume uniformity to compendial limits on every ampoule and vial format. Batch records, deviation reports and any out-of-specification investigations are reviewed by qualified persons before release, and a retained sample of every batch is held for its full shelf life so that any question raised by DGPML, a distributor or a humanitarian procurement partner can be traced back to source.
Behind release testing sits the stability programme that supports the dossier itself. Stability runs on three batches under long-term, intermediate and accelerated conditions per ICH Q1A, with photostability per ICH Q1B. Chad's Sahelian hot-dry climate is generally treated as ICH Climatic Zone III to Zone IVa for filing purposes - materially different from the hot-humid Zone IVb conditions used for coastal West and Central African markets - and we hold data across that range so a dossier can be built to whichever condition DGPML expects for a given product. Given that a meaningful share of Chad's injectable demand ultimately reaches rural clinics and refugee-camp health posts served by partners such as UNHCR and Global Fund-financed programmes, where cold-chain infrastructure is limited, we prioritise thermostable formulations wherever a validated option exists.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Chad for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified, ISO Class 5 facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, antimalarials, analgesics, anaesthetics and muscle relaxants, cardiovascular and emergency medicines, and obstetric and life-saving products, in dry-powder vials, liquid ampoules, lyophilised presentations and small-volume parenterals. For Chad that maps directly onto the country's disease profile: injectable artesunate and antimalarials against a malaria burden that is the leading cause of hospital consultations, admissions and in-hospital deaths nationally; ceftriaxone and the broader parenteral antibiotic range for meningitis-belt and measles-outbreak response; oxytocin, tranexamic acid and magnesium sulphate against a maternal mortality rate historically among the highest in the world; and IV fluids and anti-infectives for the cholera resurgence tracking the regional Sudanese epidemic into eastern Chad's refugee camps.
Our CDMO services scale from a single distributor's launch portfolio to full institutional and humanitarian-channel volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, French-language artwork development, and regulatory dossiers compiled in CTD format for DGPML submission. We supply WHO-format certificates of pharmaceutical product, WHO-GMP certification, site master files, per-batch certificates of analysis against IP, BP, USP or EP monographs, and packaging built to the labelling conventions DGPML and the CEMAC framework expect. For institutional supply, we support partners working with Chad's Centrale Pharmaceutique d'Achats (CPA), the central purchasing body established in 1995 to supply essential medicines to public and private facilities, as well as the humanitarian and Global Fund-financed channels that carry a growing share of volume given the scale of the refugee response.
Buyers stay with Farbe Firma because we say plainly what actually slows a Chad launch down, and it is procedural rather than commercial. The two workstreams to start immediately, and in parallel with dossier compilation rather than after it, are securing a licensed local pharmaceutical establishment to hold the AMM and lead the DGPML filing, and completing the full consular legalisation chain for every certificate - Chad accepts no apostille shortcut. Prepare the dossier in French from the outset rather than translating late. Logistically, Chad is landlocked, and the great majority of import cargo transits via the port of Douala in neighbouring Cameroon before road transport into N'Djamena, so realistic door-to-door planning from India runs to several weeks and should be built into any tender or humanitarian-supply commitment, with generous residual shelf life quoted given the onward transit distances involved.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Chad?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, with ISO Class 5 aseptic filling areas, more than 100 injectable products and exports to over 30 countries. For Chad we provide the documentation DGPML expects: a CTD-format dossier prepared in French, a WHO-format certificate of pharmaceutical product, a WHO-GMP certificate, the site master file, per-batch certificates of analysis against BP, USP, IP or EP monographs, and ICH Q1A stability data appropriate to Chad's hot-dry Sahelian climate. We also prepare the fully consular-legalised document set your Chadian partner needs to lodge the application, since Chad does not accept a simple apostille.
How does drug registration work in Chad, and does CEMAC membership simplify it?
Registration is administered by DGPML - the Direction Generale de la Pharmacie, du Medicament et des Laboratoires - under Loi n024/PR/2000 relative a la Pharmacie. As a CEMAC member state, Chad has adopted the CTD dossier format harmonised regionally by OCEAC since 2013, which is a real advantage if you already file in CTD elsewhere, but it does not remove the requirement for a national Autorisation de Mise sur le Marche: each product still needs its own AMM from DGPML, because full mutual recognition across the CEMAC bloc is targeted for 2027 and is not yet operational. Expect the dossier and correspondence to be handled in French, the working language of both Chad's administration and the regional framework.
Do we need a local partner or licence to import injectables into Chad?
Yes. Under Loi n024/PR/2000, only a licensed pharmacist or medical officer may operate a pharmaceutical establishment in Chad, and importing medicines requires prior authorisation from DGPML that functions as a technical clearance ahead of customs release. Farbe Firma supplies the manufacturer-side package - CTD dossier, certificate of pharmaceutical product, GMP certificate, site master file, certificates of analysis, letters of authorisation and French-language artwork, together with the fully consular-legalised versions Chad requires - while your Chadian partner holds the pharmaceutical establishment licence, lodges the AMM application and manages the import authorisation process.
Which injectables are in strongest demand in Chad?
Malaria, meningitis-belt disease, maternal care and outbreak response dominate. Malaria is the leading cause of consultations (42%), hospitalisations (32%) and hospital deaths (30%) nationally, sustaining strong demand for injectable artesunate and antimalarials; Chad's position in the African meningitis belt, combined with measles and meningitis C outbreaks recorded in 2024, drives demand for ceftriaxone and the broader parenteral antibiotic range. Maternal mortality has historically been among the highest in the world, which keeps oxytocin, tranexamic acid and magnesium sulphate in constant demand, and the cholera resurgence linked to the regional Sudan crisis is driving episodic but significant demand for IV fluids and injectable antibiotics, particularly in and around the refugee camps of eastern Chad.
What are the real documentation, language and logistics constraints on shipping injectables to Chad?
The three factors that most often catch first-time exporters out are legalisation, language and inland logistics. Chad has not ratified the Hague Apostille Convention, so certificates of pharmaceutical product, GMP certificates and powers of attorney require full consular legalisation through the Chadian embassy rather than a one-step apostille, and that process takes materially longer than an apostille does - start it early and in parallel with dossier work. The dossier itself should be prepared in French from the outset, since French is the working language of both DGPML and the CEMAC/OCEAC regional framework. On logistics, Chad is landlocked and almost entirely dependent on the port of Douala in Cameroon for import cargo, followed by road transport into N'Djamena, so build several weeks of realistic door-to-door transit time into any tender or humanitarian-supply delivery commitment, and quote generous residual shelf life given the distances involved.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments